RU2013122843A - Гликоформы антитела против фолатного рецептора альфа - Google Patents

Гликоформы антитела против фолатного рецептора альфа Download PDF

Info

Publication number
RU2013122843A
RU2013122843A RU2013122843/10A RU2013122843A RU2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843/10 A RU2013122843/10 A RU 2013122843/10A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
seq
monoclonal antibody
internalization
Prior art date
Application number
RU2013122843/10A
Other languages
English (en)
Russian (ru)
Inventor
Филип М. САСС
Николас НИКОЛЭЙДЕС
Луиджи Грассо
Эрик РУТЬЕ
Вэй ГУ
Джейсон ЯНГ
Цзюнь ЯО
Original Assignee
Морфотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Морфотек, Инк. filed Critical Морфотек, Инк.
Publication of RU2013122843A publication Critical patent/RU2013122843A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2013122843/10A 2010-10-20 2011-10-19 Гликоформы антитела против фолатного рецептора альфа RU2013122843A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Publications (1)

Publication Number Publication Date
RU2013122843A true RU2013122843A (ru) 2014-11-27

Family

ID=45975873

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013122843/10A RU2013122843A (ru) 2010-10-20 2011-10-19 Гликоформы антитела против фолатного рецептора альфа

Country Status (12)

Country Link
US (1) US20120164137A1 (cg-RX-API-DMAC7.html)
EP (1) EP2629798A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014505012A (cg-RX-API-DMAC7.html)
KR (1) KR20140032944A (cg-RX-API-DMAC7.html)
CN (1) CN103347537A (cg-RX-API-DMAC7.html)
AU (2) AU2011317088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013009275A2 (cg-RX-API-DMAC7.html)
CA (1) CA2815080A1 (cg-RX-API-DMAC7.html)
IL (1) IL225579A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013004202A (cg-RX-API-DMAC7.html)
RU (1) RU2013122843A (cg-RX-API-DMAC7.html)
WO (1) WO2012054654A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック, インコーポレイテッド 胃癌の治療のための方法
SG11201500938XA (en) * 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
CN104884617B (zh) 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
CA2969225C (en) * 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
EP3765521A4 (en) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054048A1 (en) * 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
BRPI0514068B8 (pt) * 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Also Published As

Publication number Publication date
WO2012054654A3 (en) 2012-08-02
CN103347537A (zh) 2013-10-09
AU2011317088A1 (en) 2013-05-02
MX2013004202A (es) 2013-10-17
US20120164137A1 (en) 2012-06-28
EP2629798A2 (en) 2013-08-28
AU2011317088B2 (en) 2016-01-21
CA2815080A1 (en) 2012-04-26
AU2016202082A1 (en) 2016-04-28
JP2014505012A (ja) 2014-02-27
BR112013009275A2 (pt) 2017-06-20
WO2012054654A2 (en) 2012-04-26
EP2629798A4 (en) 2014-05-28
KR20140032944A (ko) 2014-03-17
IL225579A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
JP2014505012A5 (cg-RX-API-DMAC7.html)
AU2025204722A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
KR102244173B1 (ko) 세포상해 유도 치료제
UA130461C2 (uk) Композиція окиснених варіантів афліберцепту
JP7854991B2 (ja) 新規の抗lilrb2抗体および誘導体生成物
IL310938A (en) Anti-CCR8 antibodies and their uses
PE20140614A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
CA3055438A1 (en) Multispecific antibody constructs binding to muc1 and cd3
US20220144938A1 (en) Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases
JP2014505012A (ja) 抗葉酸受容体アルファ抗体の糖型
CA3143989A1 (en) Targeting alpha3beta1 integrin for treatment of cancer and other diseases
CN113728008A (zh) 抗cd40抗体及其用途
EP3076980A1 (en) A method of treating neoplasia
CN121248787B (zh) 一种人源化抗人muc1单克隆抗体及其应用
WO2021056025A2 (en) Anti-epha10 antibodies and methods of use thereof
CN104707136A (zh) 新型双功能抗体偶联物及其制法和用途
EP4247496A1 (en) Anti-cd25 antibodies
CN104651314B (zh) 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
RU2013139743A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
JP7599716B2 (ja) がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化
CN107460221A (zh) 一种降低抗pd‑l1抗体中蛋白聚合物的细胞培养方法
EP4274617A1 (en) An agr2xcd3 bispecific engager for the treatment of cancer
WO2022106665A1 (en) Anti-cd25 antibodies
RU2535982C1 (ru) Штамм культивируемых гибридных клеток животного mus musculus l. cchfv vd-1-продуцент моноклонального антитела 4g4/b6 к вирусу крым-конго геморрагической лихорадки
WO2026085488A1 (en) Bispecific antigen binding compositions for targeting solid tumors

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160617